期刊文献+

阿加曲班与尿激酶联用致低纤维蛋白原血症

Hypofibrinogenemia induced by argatroban combined with urokinase
原文传递
导出
摘要 1例64岁男性患者因下肢深静脉血栓形成接受下肢静脉+下腔静脉造影以进行影像学诊断。造影前后分别予那屈肝素钙(3 d)和肝素钠抗凝。手术第3天,凝血功能检查示纤维蛋白原(FIB)2.78 g/L,活化部分凝血活酶时间(APTT)26.4 s,加用阿加曲班1.5μg/(kg·min)持续静脉泵入(22 h/d)和尿激酶60万U鞘管静脉泵入(时长2 h)。手术第4天,凝血功能检查示FIB 0.1 g/L,APTT 94.7 s。考虑药物所致,停用尿激酶,将阿加曲班减量至1.0μg/(kg·min),加用人纤维蛋白原。手术第5天,凝血功能检查示FIB 0.49 g/L、APTT 51.2 s,停用阿加曲班。手术第8天,凝血功能检查示FIB 1.30 g/L、APTT 31.8 s,给予新鲜冰冻血浆750 ml静脉滴注、2次/d。手术第11天,凝血功能检查示FIB 2.40 g/L,APTT 28.3 s。 A 64‑year‑old male patient underwent diagnostic imaging of lower extremity venography plus inferior vena cava angiography due to deep vein thrombosis of lower extremity.Nadroparin calcium anticoagulation was given for 3 days before the operation,and heparin sodium anticoagulation was given after the operation.On the 3rd day of the operation,the coagulation function test showed fibrinogen(FIB)2.78 g/L,activated partial thromboplastin time(APTT)26.4 s.Continuous intravenous pumping of argatroban 1.5μg/(kg·min)(22 hours daily)and intravenously pumping of urokinase 600000 U(lasting 2 hours)were given.On the 4th day of operation,the coagulation function test showed FIB 0.1 g/L and APTT 94.7 s.Considering the possible relation to drugs,urokinase was stopped,the dose of argatroban was reduced to 1.0μg/(kg·min),and human fibrinogen was added.On the 5th day of operation,the coagulation function test showed FIB 0.49 g/L and APTT 51.2 s,and argatroban was stopped.On the 8th day of operation,the coagulation function test showed FIB 1.30 g/L and APTT 31.8 s,and fresh frozen plasma 750 ml was given twice daily by intravenous infusion.On the 11th day of operation,the coagulation function test showed FIB 2.40 g/L and APTT 28.3 s.
作者 刘声野 高年婷 武新安 李波霞 Liu Shengye;Gao Nianting;Wu Xin'an;Li Boxia(Department of Interventional Medicine,the First Hospital of Lanzhou University,Lanzhou 730000,China;Department of Pharmacy,Qinghai Traffic Hospital,Xining 810000,China;Department of Pharmacy,the First Hospital of Lanzhou University,Lanzhou 730000,China)
出处 《药物不良反应杂志》 CSCD 2022年第11期609-611,共3页 Adverse Drug Reactions Journal
基金 甘肃省卫生行业科研计划项目(GSWSKY‑2019‑70)。
关键词 静脉血栓形成 低纤维蛋白原血症 阿加曲班 尿激酶 Venous thrombosis Hypofibrinemia Argatroban Urokinase
  • 相关文献

参考文献10

二级参考文献75

  • 1曹丰,陈燕敏.丙戊酸钠血药浓度监测及意义[J].中国药物应用与监测,2005,2(6):23-25. 被引量:11
  • 2何清,王菁华,刘亚林.丙戊酸钠注射液致血小板、纤维蛋白原严重减少[J].药物不良反应杂志,2005,7(6):433-433. 被引量:10
  • 3HERRICK S, BLANC- BRUDE O, GRAY A, LAURENT G. Fibrinogen[ J]. Int J Cell Bio1,1999,31:741-6.
  • 4ScRENSEN B, LARSEN OH, PlEA C J, TANG M, FOLEY JH, FENGER-ERIKSEN C. Fibrinogen as a hemostatic agent [ J ]. Semin Thromb Hemost ,2012,38:268-73.
  • 5FIBRINOGEN STUDIES COLLABORATION, DANESH J, LEWINGTON S, THOMPSON SG, LOWE GD, COLLINS R, et al. Plasma fibrinogen level and the risk of major cardio- vascular diseases and nonvascularmortality: an individual participantmeta- analysis [ J ]. JAMA, 2005,294 : 1799 - 809.
  • 6WOODS A, BRULL DJ, HUMPHRIES SE, MONTGOMERY HE. Genetics of inflammation and risk of coronary artery dis- ease :the central role of interleukin-6 [ J 1. Eur Heart J, 2000,21 : 1574-83.
  • 7辛晓敏.纤溶异常性疾病的实验室检测与应用[A].中华医学会、中华医学会检验分会、中国医院协会临床检验管理专业委员会.中华医学会第九次全国检验医学学术会议暨中国医院协会临床检验管理专业委员会第六届全国临床检验实验室管理学术会议论文汇编[c].中华医学会、中华医学会检验分会、中国医院协会临床检验管理专业委员会,2011,1.
  • 8ESTHER RABIZADEH, IZHACK CHERNY, DORON LEDERFEIN, et al. The cell- membrane prothrombinase, fi- brinogen-hke protein 2,promotes ngiogenesis and tumor de- velopment[ J]. Thrombosis Research ,2014,1-4.
  • 9CHANTELLE M, REIN- SMITH AND FRANK C. CHURCH. Emerging pathophysiological roles for fibrinolysis [ J ]. Pathophysiology and fibrinolysis Rein-Smith and Church,2014,21:438-444.
  • 10KATRIN HEFLER- FRISCHMUTH, JUDITH LAFLEUR, LUKAS HEFLER, et al. Plasma fibrinogen levels in patients with benign and malignant ovarian tumors [ J ]. Gynecologic Oncology,2015,4-4C.

共引文献1102

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部